Aldevron Capacity Update May 2024: Cell & Gene Therapy

With 25 years of service, Aldevron has manufactured high-quality research and GMP grade plasmid DNA, mRNA, and protein for partners developing vaccines, gene and cell therapies, immunotherapies, molecular diagnostics, and other genomic therapeutics. We continue to expand our offering to meet the demand of our clients, which now includes integrated mRNA-LNP Drug Product manufacturing solutions. In our presentation we will highlight the new capacity and capabilities of our complete mRNA Ecosystem to offer streamlined services for process development, manufacture and release of both mRNA drug substance and product with aseptic fill/finish.